Effect of Melatonin onImproving Fertility in Women with Diminished Ovarian Reserve

Evaluation of the Effect of Melatonin on the Follicular Oxidative Stress and Quality of Oocyte and Embryo in Women with Diminished Ovarian Reserve

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170529034209N2

Enrollment

Registered

2022-11-15

Start date

2022-12-01

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished ovarian reserve (DOR). Primary ovarian failure

Interventions

The intervention group of 38 patients with Diminished Ovarian Reserve (based on Inclusion and exclusion criteria) three months after taking one melatonin tablet (3 mg melatonin tablet Hakim) per day..

Eligibility

Sex/Gender

Female

Age

25 Years to 50 Years

Inclusion criteria

Inclusion criteria: ART for the first time normal uterine cavity presence of two of the three following criteria first; summation of bilateral AFC = 6, second; AMH=1 and third; basal FSH on the 3rd day of menstrual cycle=10.

Exclusion criteria

Exclusion criteria: If the couple decline to participatestudy the protocol is not exactly followed the ovaries showed poor responses to gonadotropins the cases

Design outcomes

Primary

Measure	Time frame
Number of ovum have received in each IVF cycle. Timepoint: On day of ovum pick up. Method of measurement: Measuring number of ovumes on the day of pick up in lab by the embryologist under microscope (GV , MI , MII ) and quality of emberyo also by the same pathologist due to kind of cell division ( Grade I , II , III , IV).;Quality of ovum have received in each IVF cycle. Timepoint: On day of ovum pick up. Method of measurement: evaluation quality of ovumes on the day of pick up in lab by an embryologist under the microscope (GV , MI , MII ) and quality of embryo also by the same pathologist due to kind of cell division ( Grade I , II , III , IV).;Quality of emberyo have received in each IVF cycle. Timepoint: On day of emberyo insercion (IVF). Method of measurement: quality of emberyo on the day of pick up in lab by pathologist under microscope (GV , MI , MII ) and quality of emberyo also by the same pathologist due to kind of cell division ( Grade I , II , III , IV).;Expression of the GDF9,BMP15, NRF -2 genes. Timepoint: On day of ovum pick up. Method of measurement: QRT-PCR.;Superoxide dismutase enzyme. Timepoint: On day of ovum pick up. Method of measurement: spectrophotometry.;The level of luteinizing hormone (LH),FSH,E2. Timepoint: menstrual cycle. Method of measurement: ELISA.	—

Measure

Time frame

Number of ovum have received in each IVF cycle. Timepoint: On day of ovum pick up. Method of measurement: Measuring number of ovumes on the day of pick up in lab by the embryologist under microscope (GV , MI , MII ) and quality of emberyo also by the same pathologist due to kind of cell division ( Grade I , II , III , IV).;Quality of ovum have received in each IVF cycle. Timepoint: On day of ovum pick up. Method of measurement: evaluation quality of ovumes on the day of pick up in lab by an embryologist under the microscope (GV , MI , MII ) and quality of embryo also by the same pathologist due to kind of cell division ( Grade I , II , III , IV).;Quality of emberyo have received in each IVF cycle. Timepoint: On day of emberyo insercion (IVF). Method of measurement: quality of emberyo on the day of pick up in lab by pathologist under microscope (GV , MI , MII ) and quality of emberyo also by the same pathologist due to kind of cell division ( Grade I , II , III , IV).;Expression of the GDF9,BMP15, NRF -2 genes. Timepoint: On day of ovum pick up. Method of measurement: QRT-PCR.;Superoxide dismutase enzyme. Timepoint: On day of ovum pick up. Method of measurement: spectrophotometry.;The level of luteinizing hormone (LH),FSH,E2. Timepoint: menstrual cycle. Method of measurement: ELISA.

—

Secondary

Measure	Time frame
Clinical pregnancy. Timepoint: 4 – 6 weeks after emberyo transfering. Method of measurement: Serum BHCG and TVS.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hojjat Ghasemnejad- berenji

Oroumia University of Medical Sciences

Ghasemnejadberenji.h@umsu.ac.ir+98 44 3346 5079

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026